8-K: Foghorn Therapeutics Announces Promising Preclinical Data for Novel Cancer Therapies

Foghorn Therapeutics presented encouraging preclinical data for its BRM selective inhibitor, FHD-909, and selective CBP and EP300 degrader programs at the 2024 AACR Annual Meeting.

Summary

• Foghorn Therapeutics is developing novel cancer therapies targeting the chromatin regulatory system.
• The company presented preclinical data at the AACR 2024 Annual Meeting for FHD-909, a BRM selective inhibitor, and selective CBP and EP300 degrader programs.
• FHD-909 demonstrated approximately 30-fold selectivity for BRM inhibition over BRG1 in cell-based assays.
• FHD-909 showed dose-dependent tumor growth inhibition and regression in multiple BRG1 mutant xenograft models.
• The selective CBP degrader program showed significant tumor growth inhibition in solid tumor models without thrombocytopenia or anemia.
• The selective EP300 degrader program demonstrated anti-tumor activity in prostate and hematological malignancies without affecting platelet levels or megakaryocyte viability.
• Foghorn is advancing FHD-286, a dual BRM/BRG1 inhibitor, in a Phase 1 dose-escalation study in combination with decitabine for relapsed/refractory AML.
• The company anticipates data from the FHD-286 combination study in the second half of 2024.
• An IND filing for FHD-909 is expected in Q2 2024, in partnership with Lilly.
• Foghorn has $234.1 million in cash and equivalents as of December 31, 2023, providing a runway into the first half of 2026.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical data and progress towards clinical trials, with a strong financial position and a major partnership. The sentiment is very positive, but tempered by the inherent risks of drug development.

Positives

• FHD-909 shows strong selectivity and efficacy in preclinical models, suggesting a potential new treatment for BRG1 mutated cancers.
• The selective CBP and EP300 degrader programs demonstrate promising anti-tumor activity with favorable safety profiles.
• The company's Gene Traffic Control platform is enabling the discovery of novel drug targets.
• The collaboration with Lilly provides significant financial and development support.
• The company has a strong cash position, providing a runway into H1 2026.

Negatives

• The company's programs are still in early stages of development, with no approved products.
• Clinical trials are subject to risks and uncertainties, and results may not be as promising as preclinical data.
• The company is dependent on its collaboration with Lilly for the development of FHD-909.
• The company's success depends on its ability to obtain regulatory approvals for its product candidates.

Risks

• Clinical trials may not be successful, and product candidates may not receive regulatory approval.
• The company's research and development efforts may not lead to commercially viable products.
• The company may face competition from other companies developing similar therapies.
• The company's financial performance is dependent on its ability to raise additional capital.
• The company's collaboration with Lilly may not be successful.

Future Outlook

The company anticipates data from the Phase 1 study of FHD-286 in combination with decitabine in H2 2024 and expects to file an IND for FHD-909 in Q2 2024. They also plan to advance their preclinical assets towards IND filings.

Management Comments

• Adrian Gottschalk, President and CEO, stated that they are pleased with the encouraging data for their highly selective and potent drug candidates.
• Adrian Gottschalk believes FHD-909 offers a potential new approach for the treatment of cancer.
• Steve Bellon, PhD, Chief Scientific Officer, noted that their selective CBP program demonstrates significant tumor growth inhibition without thrombocytopenia or anemia.
• Steve Bellon also stated that their selective EP300 program demonstrates promising preclinical efficacy with no thrombocytopenia or negative effects on megakaryocyte viability.

Industry Context

Foghorn is operating in the competitive oncology space, focusing on novel targets within the chromatin regulatory system. Their approach to targeting previously difficult-to-drug proteins like CBP and EP300 with selective degraders is a notable trend in the industry. The collaboration with Lilly highlights the growing interest in precision medicine and targeted therapies.

Comparison to Industry Standards

• Foghorn's approach to targeting the chromatin regulatory system is unique compared to traditional oncology drug development, which often focuses on kinases or immune checkpoints.
• The development of selective inhibitors and degraders for proteins like BRM, CBP, and EP300 is challenging due to their high homology, and Foghorn's progress in this area is notable.
• Companies like Arvinas and C4 Therapeutics are also developing protein degraders, but Foghorn's focus on chromatin regulators differentiates them.
• The 50/50 collaboration with Lilly is similar to other big pharma partnerships in the biotech space, where large companies provide funding and expertise in exchange for a share of the economics.
• The reported cash runway into H1 2026 is a positive sign for the company's financial stability, which is comparable to other clinical-stage biotech companies.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising preclinical data and potential for future revenue.
• Employees may be motivated by the progress of the company's research and development efforts.
• Patients with cancer may benefit from the development of new and effective therapies.
• The collaboration with Lilly may provide additional resources and expertise for the company's programs.

Next Steps

• The company plans to file an IND for FHD-909 in Q2 2024.
• They will continue the Phase 1 dose-escalation study of FHD-286 in combination with decitabine.
• They will advance preclinical assets (BRM Selective Degrader, CBP, EP300, ARID1B) towards INDs.

Key Dates

Keywords

Foghorn Therapeutics, FHD-909, BRM inhibitor, CBP degrader, EP300 degrader, chromatin biology, cancer therapy, preclinical data, AACR, Lilly, FHD-286, AML, NSCLC